Insights into the management of older patients with multiple myeloma.

Insights into the management of older patients with multiple myeloma. Clin Adv Hematol Oncol. 2019 Jul;17(7):390-392 Authors: Anderson KC PMID: 31449504 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Related Links:

ConclusionsPCPs report several barriers in providing care to hematologic malignancy/HCT survivors. Clinical experience with this patient population is associated with greater confidence in providing survivorship care. Several barriers identified by PCPs in providing survivorship care to hematologic malignancy/HCT survivors are potentially addressable by education, clinical decision support tools and guidelines, enhancing clinical experience, and care coordination with hematologist-oncologists.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Condition:   Multiple Myeloma Interventions:   Drug: Hydroxychloroquine;   Drug: Carfilzomib Injection;   Drug: Dexamethasone Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Oslo University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed And-or Refractory Multiple Myeloma and Plasmacytoid Lymphoma Intervention:   Biological: BCMA-CD19 cCAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed/Refractory, High Risk Multiple Myeloma Intervention:   Biological: CD4 CAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone) Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Intervention:   Biological: BCMA-PD1-CART Cell Sponsor:   Chinese PLA General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Hydroxychloroquine;   Drug: Carfilzomib Injection;   Drug: Dexamethasone Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Oslo University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed And-or Refractory Multiple Myeloma and Plasmacytoid Lymphoma Intervention:   Biological: BCMA-CD19 cCAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed/Refractory, High Risk Multiple Myeloma Intervention:   Biological: CD4 CAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone) Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Hematology | Myeloma